临床进展与转移性去势抵抗性前列腺癌各线治疗不良预后相关:CATS国际数据库
该研究基于CATS国际登记数据库669例连续mCRPC患者,按一线、二线和三线延长生存治疗启动时的进展类型(仅PSA、影像学或临床进展)进行事后分析,主要终点为总生存期。结果显示临床进展组中位OS较仅PSA进展组更短(一线相差14个月,二线和三线约相差7个月),无进展生存期亦更短。结论认为临床进展提示侵袭性疾病特征和不良结局,日常实践中出现临床进展早期迹象可能应启动新治疗而不依赖PSA水平。
要点
- 临床进展组mCRPC患者一线治疗中位OS较仅PSA进展组短14个月,二线和三线约短7个月。
- 无论接受何种治疗,临床进展患者的中位PFS均更短。
- 临床进展似与雄激素受体靶向治疗(ART)疗程较紫杉类更短相关。
核心结论
- 在mCRPC患者启动延长生存治疗时,临床进展与更短PFS和OS以及侵袭性疾病的临床和生物学特征相关。
研究设计与样本
- 基于CATS国际登记数据库669例连续mCRPC患者的事后分析,按一线、二线和三线延长生存治疗启动时的进展类型分组。
- 进展类型分为仅PSA进展(PSA-p)、影像学进展(±PSA)(Radio-p)和临床进展(±PSA、±影像学)(Clin-p)。
- 主要终点OS从一线、二线和三线延长生存治疗启动时计算至死亡。
主要发现
- 临床进展组中位OS较仅PSA进展组更短:一线相差14个月,二线和三线约相差7个月。
- 无论接受何种治疗,临床进展患者的中位PFS均更短。
- 临床进展似与雄激素受体靶向治疗(ART)疗程较紫杉类更短相关。
临床怎么用
- 日常实践中,临床进展的早期迹象可能促使医生考虑启动新的延长生存治疗,而不依赖PSA水平。
- 在临床试验中按疾病进展类型对患者分层可能有助于避免选择偏倚和数据异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM OF THE STUDY: Our goal was to evaluate the impact of progression type (prostate-specific antigen [PSA] only, radiological or clinical) at initiation of first-, second- and third life-extending therapy (LET) on treatment outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients, by performing a post-hoc analysis using data from the CATS international registry. METHODS: The 669 consecutive mCRPC patients of the CATS registry were classified according to their type of progression at initiation of each LET: PSA only (PSA-p), radiological (±PSA) (Radio-p); or clinical (±PSA, ±radiological) progression (Clin-p). Overall survival (OS), the primary endpoint, was calculated from initiation of the first-, second- and third-LET to death for each sequence. RESULTS: Median OS was shorter in the Clin-p group compared with the PSA-p group (14-month difference in first line; around 7-month difference in second- and third line). Shorter progression-free survival (PFS) was also observed in Clin-p patients, whatever the treatment is. Clinical progression seemed to be associated with a shorter duration of therapy with androgen receptor-targeted therapy (ART) compared with taxanes. CONCLUSIONS: Clinical progression at initiation of a LET is associated with poor outcomes including shorter PFS and OS as well as clinical and biological features of aggressive disease. Stratifying patients in clinical trials according to disease progression type may prevent selection bias and data heterogeneity. In daily practice, first signs of clinical progression may prompt physicians to consider starting a new LET, independently of PSA levels.
引用
- Delanoy N, Hardy-Bessard AC, Efstathiou E, et al. Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. Eur J Cancer. 2019. PMID: 31787484. doi:10.1016/j.ejca.2019.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。